tetano
Editor, Senior Moderator
J Clin Med
. 2020 Jun 30;9(7):E2050.
doi: 10.3390/jcm9072050.
Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives
Simone Meini[SUP] 1 [/SUP], Alberto Pagotto[SUP] 2 [/SUP], Benedetta Longo[SUP] 3 [/SUP], Igor Vendramin[SUP] 4 [/SUP], Davide Pecori[SUP] 2 [/SUP], Carlo Tascini[SUP] 2 [/SUP]
Affiliations
Abstract
A life-threatening respiratory illness (COVID-19) due to severe acute respiratory syndrome (SARS)-CoV-2 coronavirus was first described in December 2019 in Wuhan (China), rapidly evolving into a pandemic. In the first phase, when the viral replication plays a pivotal pathogenetic role, antiviral drugs could be crucial in limiting viral-induced organ damage. Unfortunately, there are no specific antivirals of proven efficacy for COVID-19, and several drugs have been repurposed to face this dramatic pandemic. In this paper we review the studies evaluating lopinavir/ritonavir association (LPV/r) use in COVID-19, and previously in SARS and Middle East respiratory syndrome (MERS). We searched PubMed to identify all relevant clinical and laboratory studies published up to 15 May 2020; the guidelines on the use of LPV/r in COVID-19 were further directly searched on the website of the main international scientific societies and agencies. Available evidence is currently scarce and of low quality. The recommendations issued for COVID-19 vary from positions clearly against the use of LPV/r to other positions that are more favorable. In our opinion, despite the controversial results of an important randomized clinical trial, and some recommendations, clinicians should not abandon the use of LPV/r for the treatment of COVID-19, possibly using this drug inside a prospective randomized trial, waiting for the results of the numerous ongoing trials evaluating its efficacy.
Keywords: COVID-19; MERS; SARS; guideline; lopinavir; recommendation; ritonavir.
. 2020 Jun 30;9(7):E2050.
doi: 10.3390/jcm9072050.
Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives
Simone Meini[SUP] 1 [/SUP], Alberto Pagotto[SUP] 2 [/SUP], Benedetta Longo[SUP] 3 [/SUP], Igor Vendramin[SUP] 4 [/SUP], Davide Pecori[SUP] 2 [/SUP], Carlo Tascini[SUP] 2 [/SUP]
Affiliations
- PMID: 32629768
- DOI: 10.3390/jcm9072050
Abstract
A life-threatening respiratory illness (COVID-19) due to severe acute respiratory syndrome (SARS)-CoV-2 coronavirus was first described in December 2019 in Wuhan (China), rapidly evolving into a pandemic. In the first phase, when the viral replication plays a pivotal pathogenetic role, antiviral drugs could be crucial in limiting viral-induced organ damage. Unfortunately, there are no specific antivirals of proven efficacy for COVID-19, and several drugs have been repurposed to face this dramatic pandemic. In this paper we review the studies evaluating lopinavir/ritonavir association (LPV/r) use in COVID-19, and previously in SARS and Middle East respiratory syndrome (MERS). We searched PubMed to identify all relevant clinical and laboratory studies published up to 15 May 2020; the guidelines on the use of LPV/r in COVID-19 were further directly searched on the website of the main international scientific societies and agencies. Available evidence is currently scarce and of low quality. The recommendations issued for COVID-19 vary from positions clearly against the use of LPV/r to other positions that are more favorable. In our opinion, despite the controversial results of an important randomized clinical trial, and some recommendations, clinicians should not abandon the use of LPV/r for the treatment of COVID-19, possibly using this drug inside a prospective randomized trial, waiting for the results of the numerous ongoing trials evaluating its efficacy.
Keywords: COVID-19; MERS; SARS; guideline; lopinavir; recommendation; ritonavir.